Background: Tumor-infiltrating lymphocytes (TILs) can be used to monitor the immune response, and are important in predicting treatment responses and outcomes for various types of cancer. In this study, we evaluated the prognostic significance of CD8 þ TILs and FOXP3 þ TILs before and after neoadjuvant chemotherapy (NAC).
Methods: Except for patients who achieved pathological complete response, 136 breast cancer patients treated with NAC were examined. CD8
þ TILs and FOXP3 þ TILs in biopsy specimens and residual tumors were evaluated by immunohistochemistry. CD8
þ TILs and FOXP3 þ TILs status was assessed, and the rates of their changes before and after NAC were calculated. Results: All patients with high rates of changes in the CD8
þ TILs or low rates of changes in the FOXP3
þ TILs or high rates of changes in the CD8/FOXP3 ratio (CFR) had significantly better recurrence-free survival (RFS) (P ¼ 0.006, P ¼ 0.044, P < 0.001, respectively) and overall survival (OS) (P ¼ 0.037, P ¼ 0.025, P < 0.001, respectively). In multivariate analysis, rates of changes in the CD8 þ TILs and rates of changes in the CFR were an independent predictor for RFS (hazard ratio (HR) ¼ 2.304, 95% confidence interval (CI) 1.052-5.776, P ¼ 0.036; HR ¼ 4.663, 95% CI 2.133-11.68, P < 0.001, respectively). Pathological response was also significantly correlated with RFS (HR ¼ 5.260, 95% CI 2.373-11.14, P < 0.001). Of the 39 patients with triple-negative breast cancer, rates of changes in the CFR were independent predictor for RFS (HR ¼ 13.02, 95% CI 2.241-258.1, P ¼ 0.002). Of the 78 patients with hormone receptor-positive breast cancer, rates of changes in the CFR were significantly correlated with RFS too (HR ¼ 4.377, 95% CI 1.641-13.71, P ¼ 0.003). Conclusions: Improvement in immune microenvironment following NAC has a relationship with good outcome. In particular, rates of changes in the CFR may be a useful biomarker to predict prognosis of patients treated with NAC in all breast cancer subtypes. Legal entity responsible for the study: Shinichiro Kashiwagi Funding: None Disclosure: All authors have declared no conflicts of interest. Background: IBM Watson for Oncology (WFO) is a Memorial Sloan Kettering-trained cognitive computing system that uses natural language processing (NLP) to ingest data in structured and unstructured formats. WFO provides physicians with evidence-based treatment options and ranks them into three categories for oncology treatment decision support. This study examined the degree of concordance between treatment recommendation supposed by WFO and a multi-disciplinary tumor board in The Affiliated Hospital of Qingdao University. Methods: Retrospective data from 152 cancer patients were ingested into WFO from Aug, 2015 to Jul, 2017. WFO recommendations were provided in 3 categories: "Recommended", "For Consideration", and "Not Recommended." Concordance was analyzed by comparing the treatment decisions proposed by WFO to those of the multi-disciplinary tumor board. Concordance was achieved when the multi-disciplinary tumor boards' treatment decisions were in the "Recommended" or "For Consideration" categories in WFO. Background: Recently, precision medicine has gained attention for the prediction of therapeutic strategies in individual patients. Because the biological behavior of tumor cells has changed over time according to the pressures from treatment, real-time monitoring of tumor biology is needed to provide suitable information for choosing the most effective therapy for each patient. Circulating tumor cells (CTCs) can reflect current tumor status from primary sites and metastases from the bloodstream without invasive testing. In the current CTCs capture platforms of flow cytometry, gradient centrifugation, filtration, and droplets have been employed. A novel label-free inertial microfluidics approach (MFA) based on biomechanical properties has been developed at National Singapore University (Hou et al, Sci Rep 2013) , and is able to capture CTCs independent of EpCAM expression. To identify genomic alterations in CTCs as basic data for precision medicine, we investigated the genomic profiling of CTCs using nextgeneration sequencing (NGS). Methods: Participants in this prospective study comprised 31 patients with advanced head and neck cancer (HN), esophageal cancer (EC), gastric cancer (GC), or colorectal cancer (CRC). CTCs were isolated using an MFA technique from 5 ml of whole blood. NGS was performed after whole-genome amplification (WGA) of DNA extracted from CTCs. Results: The underlying pathology was HN in 11 patients, EC in 8 patients, GC in 1 patient, and CRC in 11 patients. CTCs were detected from the peripheral blood of all patients (median number of CTCs, 14.5/ml; range, 3-133/ml). The most frequently detected mutations in CTCs were to APC, EGFR, RB1 and SMAD4 (10.5%) in HN and EC, and TP53 (27.2%), MET, RB1, and SMAD4 (18.2%) in CRC. NGS was successfully performed using WGA-treated DNA from CTCs and related material. Conclusions: We were able to effectively capture CTCs from patients with HN, EC, GC and CRC, and successfully performed NGS of CTCs using a microfluidic separation system without antibodies. Another trial is now ongoing to assess correlations between emergence of gene mutations in CTCs and changes in therapeutic effect during molecular-targeted therapy. TRANSLATIONAL RESEARCH
